175 related articles for article (PubMed ID: 31938082)
21. Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis.
Rauterberg EW; Lieberknecht HM; Wingen AM; Ritz E
Kidney Int; 1987 Mar; 31(3):820-9. PubMed ID: 3573542
[TBL] [Abstract][Full Text] [Related]
22. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
Subías Hidalgo M; Yébenes H; Rodríguez-Gallego C; Martín-Ambrosio A; Domínguez M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Eur J Immunol; 2017 Mar; 47(3):504-515. PubMed ID: 28083930
[TBL] [Abstract][Full Text] [Related]
23. Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopy.
Alcorlo M; Martínez-Barricarte R; Fernández FJ; Rodríguez-Gallego C; Round A; Vega MC; Harris CL; de Cordoba SR; Llorca O
Proc Natl Acad Sci U S A; 2011 Aug; 108(32):13236-40. PubMed ID: 21788512
[TBL] [Abstract][Full Text] [Related]
24. Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.
Carpanini SM; Torvell M; Bevan RJ; Byrne RAJ; Daskoulidou N; Saito T; Saido TC; Taylor PR; Hughes TR; Zelek WM; Morgan BP
Acta Neuropathol Commun; 2022 Jul; 10(1):99. PubMed ID: 35794654
[TBL] [Abstract][Full Text] [Related]
25. A comparative evaluation of receptor reactivities for C3b, iC3b, and C3d on Raji lymphoblastoid cells.
Scheiner O; Hammann KP; Schmid HU; Schulz T; Alsenz J; Dierich MP
Int Arch Allergy Appl Immunol; 1982; 69(3):231-7. PubMed ID: 6215359
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates.
Yefenof E; Benizri R; Reiter Y; Klein E; Fishelson Z
J Immunol; 1990 Feb; 144(4):1538-43. PubMed ID: 2303717
[TBL] [Abstract][Full Text] [Related]
27. Complement activation following reoxygenation of hypoxic human endothelial cells: role of intracellular reactive oxygen species, NF-kappaB and new protein synthesis.
Collard CD; Agah A; Stahl GL
Immunopharmacology; 1998 Mar; 39(1):39-50. PubMed ID: 9667422
[TBL] [Abstract][Full Text] [Related]
28. Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients.
Ge X; Yu Z; Guo X; Li L; Ye L; Ye M; Yuan J; Zhu C; Hu W; Hou Y
Pathol Res Pract; 2023 Jul; 247():154519. PubMed ID: 37244049
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer.
Beum PV; Lindorfer MA; Hall BE; George TC; Frost K; Morrissey PJ; Taylor RP
J Immunol Methods; 2006 Dec; 317(1-2):90-9. PubMed ID: 17067631
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
32. The covalent interaction of C3 with IgG immune complexes.
Vivanco F; Muñoz E; Vidarte L; Pastor C
Mol Immunol; 1999; 36(13-14):843-52. PubMed ID: 10698338
[TBL] [Abstract][Full Text] [Related]
33. Clearance of complement by human vascular endothelial cells: effects of hypoxia/reoxygenation and IL-1beta activation.
Haun JB; Baldwin WM; Alevriadou BR
Transpl Int; 2005 Apr; 18(4):475-82. PubMed ID: 15773971
[TBL] [Abstract][Full Text] [Related]
34. Deposition of C3b/iC3b leads to the concealment of antigens, immunoglobulins and bound C1q in complement-activating immune complexes.
Nilsson UR
Mol Immunol; 2001 Aug; 38(2-3):151-60. PubMed ID: 11532277
[TBL] [Abstract][Full Text] [Related]
35. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
[TBL] [Abstract][Full Text] [Related]
36. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP
Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic intervention with complement and beta-glucan in cancer.
Ross GD; Vetvicka V; Yan J; Xia Y; Vetvicková J
Immunopharmacology; 1999 May; 42(1-3):61-74. PubMed ID: 10408367
[TBL] [Abstract][Full Text] [Related]
38. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
[TBL] [Abstract][Full Text] [Related]
39. Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b.
Hyams C; Trzcinski K; Camberlein E; Weinberger DM; Chimalapati S; Noursadeghi M; Lipsitch M; Brown JS
Infect Immun; 2013 Jan; 81(1):354-63. PubMed ID: 23147038
[TBL] [Abstract][Full Text] [Related]
40. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
DiLillo DJ; Pawluczkowycz AW; Peng W; Kennedy AD; Beum PV; Lindorfer MA; Taylor RP
Mol Immunol; 2006 Mar; 43(7):1010-9. PubMed ID: 15961157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
